Why the Starpharma (ASX:SPL) share price is down 10% today

The pharmaceutical company's shares are now in negative year-to-date territory.

| More on:
falling healthcare asx share price Mesoblast capital raising

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

Starpharma Holdings Limited (ASX: SPL) shares have taken a hit this morning. At the time of writing, the Starpharama share price is trading 9.71% lower at $1.535.

What's dragging the Starpharma share price down?

Starpharma shares are well in the red on Monday after the company advised its UK retail partner, LloydsPharmacy, has received correspondence from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) regarding the promotional claims for the company's VIRALEZE antiviral nasal spray.

According to today's statement, the correspondence is flagging the company's promotional claims, including "references to SARS-CoV-2 and COVID-19, and the interrelationship between these product claims and its categorisation".

The announcement said that the MHRA is not questioning the safety or the quality of VIRALEZE, but the "allowable promotional claims".

VIRALEZE is an antiviral nasal spray which has been shown in laboratory studies to inactivate a range of respiratory viruses, including 99.9% of SARS-CoV-2 and COVID-19.

What happens now?

Starpharma disagrees with MHRA's stance on its promotional claims and is working to resolve the matter as quickly as possible.

The company believes it has extensive data, including expert regulatory advice and input from an EU regulatory body, to support the product and its promotional claims.

However, as a resolution is sought, Starpharma has agreed to temporarily pause UK VIRALEZE sales.

The company reassures that the temporary pause in sales is specific to the UK, and does not impact other markets including Europe and India.

The update also advises that Starpharma is rapidly progressing commercialisation and supply arrangements for the Indian market.

Whipsaw like action for the Starpharma share price

Despite having rallied significantly since its March 2020 lows, the Starpharma share price has been highly volatile over the past year. The company has seen significant share price rallies followed by sharp selloffs.

Starpharma shares surged by around 50% from 25 August to a high of $1.95 on 1 September last year. This was likely driven by announcements including a strong full-year results release and positive updates for the VIRALEZE product.

But by the end of December 2020, the Starpharma share price had shed around 20% of its value and was trading at $1.565.

A similar situation occurred this year, with the company's shares rallying some 67% from 27 January to a record high of $2.52 on 16 February.

Fast forward to today, about 40% of Starpharma's market capitalisation has been wiped since its February highs.

Today's sharp selloff has now dragged the Starpharma share price into negative year-to-date territory, with 2021 returns sitting at around -2%.

Despite the company pushing ahead with regulatory activities for VIRALEZE for a number of important markets and geographies, investors are likely weighing in on the pause in UK sales.

Kerry Sun has no position in any of the stocks mentioned.  The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Starpharma Holdings Limited. The Motley Fool Australia has recommended Starpharma Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

3 ASX companies that are global leaders

Numerous ASX companies have extended their reach beyond Australia to dominate in their fields.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Bell Potter just slapped a buy on this ASX 200 share offering a 30% return

Which stock is being tipped as a buy? Let's find out.

Read more »

Happy healthcare workers in a labs
Healthcare Shares

Macquarie initiates coverage of Neuren Pharmaceuticals shares; forecasts 45% upside

The broker described Neuren as a standout in the ASX biotech sector.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Healthcare Shares

Does Macquarie think Cochlear shares are a buy, hold, or sell?

Macquarie has released a new note on Cochlear following the company's FY25 profit guidance change.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

Up 18% this year, does Macquarie expect NIB shares to go higher?

This expert has a bold prediction for NIB.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why is the Mesoblast share price up 11% in June?

The ASX biotech share reached a 10-week high of $1.94 today.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Up 51% since the tariff pain, is it too late to buy Pro Medicus shares?

After rocketing higher, is the ASX healthcare share still an opportunity?

Read more »

A woman wearing a yellow shirt smiles as she checks her phone.
Healthcare Shares

CSL shares push higher on US FDA approval

This biotech giant has been given a boost in the United States.

Read more »